



Completion of second financing round

The cancer therapy company has successfully completed its second financing round

Lyon, France, May 13, 2014 – Orega Biotech, the biotech company dedicated to the development of novel cancer therapies, announces today the completion of its second round of financing through a private investment from the historical investors, SHAM, a Lyon-based insurance company specialized in medical malpractice liability insurance, Rhône-Alpes Création, a private Venture Capital Company which invests in innovative start-ups based in the Rhone-Alpes region and OCTALFA, a French holding company managed by Gilles Alberici.

About OREGA Biotech

OREGA Biotech was set up in 2010 at the initiative of its four founders bringing together scientific, medical and business skills. OREGA Biotech specializes in the development of first-in-class monoclonal antibodies for the treatment of cancer. The current pipeline of the company focuses on the tumor microenvironment. It encompasses monoclonal antibodies targeting cancer-related inflammation and tumor immune-evasion. Our first preclinical candidate is a CD39-blocking antibody that modulates regulatory T cell and tumor cell-mediated suppression of the immune response. The second preclinical program targets the pro-inflammatory cytokine IL-17 which is involved in the progression of some tumors. Our target identification program led to the recent discovery and validation of other clinically-relevant novel cancer targets.

OREGA Biotech's business strategy is to bring in parallel several R&D programs up to proof of concept, IND or early clinical stages and then to license them out to larger biotech or pharmaceutical companies. The company is also interested in early-stage co-development agreements or partnering. OREGA Biotech is building on a strong IP strategy, high level scientific publications and relies on a strong academic and industrial network worldwide to develop clinical applications of its research programs. Today, 9 people contribute to the research programs of OREGA Biotech including the 4 founders, 3 postdoctoral researchers and 1 engineer under the supervision of the COO.

For more information, visit: www.orega-biotech.com

About SHAM

SHAM is a French mutual insurance company based in Lyon that specializes in medical malpractice liability. SHAM, which is one of the French leaders in its sector, has a portfolio of assets of 1.3 billion Euros invested in a variety of mediums. Since 2007, it has also been investing in young innovative businesses in the health industry.

For more information, visit: www.sham.fr



About Rhône-Alpes creation

Rhône-Alpes Création is a French Private Equity company. For more than 20 years, Rhône-Alpes Création mobilizes equity for young and high growth potential companies, which are based in the Rhone-Alps area. The majority of the capital is held by private sector organisms (such as banks or industries) with assistance from the regional authorities. Its intervention is systematically co-investment with other seed funds, proximity venture capitalists, or Business-angels. The investment focus is companies in biotechnologies, environment sectors and the information technology.

For more information, visit: www.r-a-c.fr

About Octalfa

Set up in 2006, Octalfa is a family-owned, independent investment company specializing in Life Sciences. Octalfa focuses on seed financing, although it also intervenes as a co-investor in later-stage companies. Octalfa recently established the Dominique et Tom Alberici-Octalfa Corporate Foundation, aiming at helping cancer patients and disabled people, as well as supporting projects designed to improve their medical care. Octalfa also supports Octalfa 360, an Investment Fund specializing in health and green technologies.

For more information, visit: www.octalfa.eu